Neonatal screening for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis: four years' experience

• Published in: BMJ 1994-06, Vol.308 (6942), p.1469-1472
• Main Authors: Ranieri, E, Lewis, B D, Gerace, R L, Ryall, R G, Morris, C P, Nelson, P V, Carey, W F, Robertson, E F
• Format: Article
• Language: English
• Subjects: Blood; Children & youth; Counseling; Cystic fibrosis; Cystic Fibrosis - diagnosis; Cystic Fibrosis - epidemiology; Cystic Fibrosis - genetics; DNA Mutational Analysis; Families & family life; Genes - genetics; Genetic Counseling; Genetic mutation; Genetic screening; Genetic Techniques; Genetic Testing - methods; Humans; Incidence; Infant, Newborn; Laboratories; Long term; Meconium; Medical genetics; Mutation; Neonatal screening; Neonatal Screening - methods; Newborns; Parents & parenting; Population; Predictive Value of Tests; Prospective Studies; Screening tests; South Australia - epidemiology; Sweat; Trypsinogen - blood
• ISSN: 0959-8138; 1468-5833; 1756-1833
• DOI: 10.1136/bmj.308.6942.1469

Abstract Objective : To assess the performance and impact of a two tier neonatal screening programme for cystic fibrosis based on an initial estimation of immunoreactive trypsinogen followed by direct gene analysis. >Design : Four year prospective study of two tier screening strategy. First tier: immunoreactive trypsinogen measured in dried blood spot samples from neonates aged 3-5 days. Second tier: direct gene analysis of cystic fibrosis mutations (δF508, δI506, G551D, G542X, and R553X) in samples with immunoreactive trypsinogen concentrations in highest 1% and in all neonates with meconium ileus20or family history of cystic fibrosis. Setting : South Australian Neonatal Screening Programme, Adelaide. Subjects : All 88 752 neonates born in South Australia between December 1989 and December 1993. Interventions : Neonates with two identifiable mutations were referred directly for clinical assessment and confirmatory sweat test; infants with only one identifiable mutation were recalled for sweat test at age 3-4 weeks. Parents of neonates identified as carriers of cystic fibrosis mutation were counselled and offered genetic testing. Main outcome measures - Identification of20all children with cystic fibrosis in the screened population. Results : Of 1004 (1.13%) neonates with immunoreactive trypsinogen >=99th centile, 912 (90.8%) had no identifiable mutation. 23 neonates were homozygotes or compound heterozygotes; 69 carried one identifiable mutation, of whom six had positive sweat tests. Median age at clinical assessment for the 29 neonates with cystic fibrosis was 3 weeks; six had meconium ileus and two had affected siblings. 63 neonates were identified as carriers of a cystic fibrosis mutation. Extra laboratory costs for measuring immunoreactive trypsinogen and direct gene analysis were $A1.50 per neonate screened. Conclusion : This strategy results in early and accurate diagnosis of cystic fibrosis and performs better than screening strategies based on immunoreactive trypsinogen measurement alone.